Skip to content

Pharmacokinetic Properties and Bioequivalence of Two Formulations of Atorvastatin 20-mg Tablets: A Randomized, Single-Dose, Three-Period, Partial Replicated Crossover Study in Healthy Chinese Male Volunteers

Pharmacokinetic Properties and Bioequivalence of Two Formulations of Atorvastatin 20-mg Tablets: A Randomized, Single-Dose, Three-Period, Partial Replicated Crossover Study in Healthy Chinese Male Volunteers

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006573
Enrollment
Unknown
Registered
2015-06-11
Start date
2013-06-24
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipoidemia

Interventions

A:3 periods: Test formulation 20mg, reference formulation 20mg, reference formulation 20mg
B:3 periods: reference formulation 20mg,Test formulation 20mg, reference formulation 20mg
C:3 periods: reference formulation 20mg, reference formulation 20mg,Test formulation 20mg

Sponsors

Beijing Anzhen Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Be able to make good communication with researchers. Understand and comply with the various requirements of the present study. Understood and signed the informed consent; (2) Male; (3) 18-40 years old, and age difference is within 10 years; (4) BMI within 19-24 kg/m2, and weight is above 50 kg; (5) Have a good health condition, according to the disease history, physical test, vital signs, ECG and clinical laboratory tests; (6) Negative results in HBsAg, HCV-IgG, HIV1/2-IgM or TPHA-IgM tests; (7) No parenting plan in six months.

Exclusion criteria

Exclusion criteria: 1. Have history of clinically significant allergic reactions, especially drug allergie; 2. Can not communicate with investigators because of neurological and psychiatric disorders or language barriers. 3. Have history of significant disease, which may affect safety and drug ADME; 4. Have disease which may affect drug ADME; 5. Drug abuse history in last 2 years; 6. Cigarette addicted, or smoking 30 days before trial; 7. Alcohol addicted, or 48 hours before dosing; 8. Take any drug in the last 3 months before the study; 9. Take any trial drug in the last 90 days before the study; 10. Blood donation over 200 mL in the last 3 months. Have plan to donate blood or blood components within 1 month after the study; 11. Subjects with hemophobia, or subjects fainting during acupuncture; 12. The subjects researchers consider are not suitable for the clinical trial, or will not complete the trials.

Design outcomes

Primary

MeasureTime frame
Plasma concentration;

Countries

China

Contacts

Public ContactLin Yang
linyang3623@163.com+86 010-64456045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026